In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy [Yahoo! Finance]
Matinas Biopharma Holdings, Inc. (MTNB)
NASDAQ:AMEX Investor Relations:
ir.matinasbiopharma.com
Company Research
Source: Yahoo! Finance
BEDMINSTER, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, demonstrated efficacy compared with placebo in treating the pulmonary mucormycosis fungal infections Rhizopus delemar and M. circinelloides f. jenssenii in immunosuppressed mice. Efficacy was demonstrated by prolonged median survival time, enhanced overall survival, reduced tissue fungal burden of target organs and improved histological architecture of infected lungs. In addition, MAT2203 activity appeared to be similar to IV-amphotericin B in survival studies in the M. circinelloides f. jenssenii mouse model. The study results are reported in the manuscript “Efficacy of an oral lipid nanocrystal (LNC) formulation of amphotericin B (MAT220
Show less
Read more
Impact Snapshot
Event Time:
MTNB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MTNB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MTNB alerts
High impacting Matinas Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
MTNB
News
- New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024 [Yahoo! Finance]Yahoo! Finance
- New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024GlobeNewswire
- Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update [Yahoo! Finance]Yahoo! Finance
- Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewswire
- Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual MeetingGlobeNewswire
MTNB
Sec Filings
- 5/9/24 - Form 8-K
- 5/9/24 - Form 10-Q
- 4/5/24 - Form 8-K
- MTNB's page on the SEC website